Indian Drug Giant Cipla Slashes Cancer Drug Prices

May 4, 2012
76% price reduction is for India market only.

Cipla, one of India's largest generic drug makers, said on May 4 that it has slashed prices by up to 76% of generic medicines used to treat brain, lung and kidney cancer in what the company called a "humanitarian move."

There are 2.5 million cases of cancer diagnosed in India each year, according to the World Health Organization, with most patients receiving inadequate treatment as drugs are priced beyond their reach.

"This initiative of price reduction is a humanitarian approach by Cipla to support cancer patients," company chairman Y.K. Hamied said in a statement, which added the price reduction would be only for drugs sold in India.

"Drugs constitute a significant proportion of the overall cost of cancer treatment and a reduction in costs can greatly relieve the burden," he said.

Cipla's step may not only help cancer patients, but "they will reach many more patients, and will also be able to garner greater market share", Anjan Sen, healthcare director at consultancy Deloitte, told the Economic Times.

"It's a smart move."

Cipla cut the price of Soranib, a generic version of Bayer's blockbuster kidney cancer drug Nexavar by 76 %, and will sell it at 6,840 rupees ($130) for a monthly dose, down from 28,000 rupees. Cipla, which has been embroiled in a legal dispute with Bayer (IW 1000/72) over its right to produce Nexavar, said cancer drugs were a small part of its business and the price cuts would not affect revenues.

But analysts said the step could prompt a price war in the 15-billion-rupee Indian drug market -- challenging multinationals which sell costly patented medicine and Indian firms whose generic range is less expensive but not as cheap as Cipla's.

"This market is price-sensitive and when larger players start cutting prices, others will likely follow," said Sudarshan Padmanabhan, pharmaceutical analyst at Mumbai investment house Prabhudas Lilladher.

The company also said the lung-cancer drug Gefticip, originally produced by AstraZeneca, would be priced at 4,250 rupees, down by over half, and it cut by three-quarters the price of brain-cancer drug Temoside, originally made by Schering, to 5,000 rupees.

Cipla makes its cancer drugs at its Goa plant, which has been approved by the U.S. Food and Drug Administration.

The family-led company first hit headlines in 2001 when it offered to supply life-saving triple therapy AIDS drug cocktails at prices sharply below those of multinational firms with Hamied saying the move was for "social reasons".

Competition among generic manufacturers in India, known as the "pharmacy to the developing world", has reduced HIV drug prices from $10,000 per person per year to $150, Medecins Sans Frontieres says.

Copyright Agence France-Presse, 2012

Popular Sponsored Recommendations

Cloud-Based OT Data Management to Enable Analytics & Optimization

April 9, 2023
Can you rapidly move all of your company's OT data to the cloud at scale at a reasonable cost? Read the white paper to find out how!

Taking Control of Inbound Supply Chains

May 22, 2023
Companies can be more efficient when they execute more control over inbound transportation. Penske Logistics has pioneered inbound strategies for over 30 years and has the scale...

Servitization: Manufacturers see the value in new pricing models

June 27, 2023
Digital transformation is causing forward-thinking manufacturers to adopt tools that accelerate the configure, price, and quote process — and they’re gaining benefits.

Electric Vehicles Spark New Opportunities in the Automotive Industry

Dec. 4, 2023
Automakers have increased plans to produce Electric Vehicles to meet customer demand for low emissions. With this radical shift, new opportunities and challenges for the auto ...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!